Longeveron’s stem cell data hint at calmer brains
A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an investor tour. Longeveron went back to its Alzheimer’s data and took a second look. The Miami company’s CLEAR MIND trial, a Phase 2a study of 49 people, already reported its main res
<p>A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an investor tour. Longeveron went back to its Alzheimer’s data and took a second look. The Miami company’s CLEAR MIND trial, a Phase 2a study of 49 people, already reported its main res</p>